Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62,861 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Deng L, Li Z, Zhang H, Huang H, Hu J, Liu L, Liu T, Jin J, Zhu Z, Li W, Huang Z, Huang W, Zhou K, Yang H, Zhang M, Ding K, Zhou H, Hu Y, Shuang Y, Cao J, Gao S, Li D, Sun Z, Zhang Q, Yi S, Ji C, Zhang L, Hou C, Du Y, Wang W, Zhao R, Song Y, Zhu J. Deng L, et al. Among authors: zhang l, zhang m, zhang q, zhang h. Am J Hematol. 2023 Nov;98(11):1742-1750. doi: 10.1002/ajh.27064. Epub 2023 Aug 30. Am J Hematol. 2023. PMID: 37647123 Free article.
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma.
Han X, Zhang M, Wang H, Zhang Q, Li W, Hao M, Gao Y, Jin J, Ren H, Tang Y, Hong X, Ke X, Su H, Gui L, Luo J, Xie L, Gai W, Shi Y. Han X, et al. Among authors: zhang m, zhang q. Chin J Cancer Res. 2022 Dec 30;34(6):601-611. doi: 10.21147/j.issn.1000-9604.2022.06.08. Chin J Cancer Res. 2022. PMID: 36714342 Free PMC article.
A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Zhang L, Dong YJ, Peng HL, Li H, Zhang MZ, Wang HH, Liu QH, Su LP, Zhong LY, Wu WJ, Huang L, Yan XJ, Fan L, Tang WJ, Li ZL, Bi LT, Li Y, Gao GX, Gao L, Liu TB, Wei YQ, Liu Y, Yu L, Zhou H, Sun CY, Qian WB, Zou DH, Zhang HL, Ding KY, Wang XB, Bai O, Huang WR, Chen B, Yang L, Song J, Gao D, Chen T, Luo J, Wang SY, Ma LM, Fajgenbaum DC, Li J; China Castleman Disease Network (CCDN). Zhang L, et al. Lancet Reg Health West Pac. 2023 Mar 24;34:100720. doi: 10.1016/j.lanwpc.2023.100720. eCollection 2023 May. Lancet Reg Health West Pac. 2023. PMID: 37283978 Free PMC article.
62,861 results
You have reached the last available page of results. Please see the User Guide for more information.